Janssen files for EU approval of canagliflozin in type 2 diabetes; Ferrer pulls Egrifta MAA

27 June 2012

US health care giant Johnson & Johnson’s (NYSE: JNJ) European subsidiary Janssen-Cilag International NV (Janssen) has submitted a Marketing Authorisation Application to the European Medicines Agency for the use of canagliflozin, an investigational, oral, once-daily sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.

Janssen and its affiliates have rights to canagliflozin through a license agreement with Japan’s Mitsubishi Tanabe Pharma (TYO: 4508) in North America, South America, Europe, the Middle East, Africa, Australia, New Zealand and parts of Asia. J&J recently filed a New Drug Application for the product in the USA for a similar indication (The Pharma Letter June 1).

The MAA submission for canagliflozin is supported by a comprehensive global Phase III clinical development program, which included nine multicenter, randomized clinical studies that enrolled around 10,300 patients, representing the largest late-stage development program for an investigational pharmacologic product for the treatment of adult patients with type 2 diabetes submitted to health authorities to date.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK